• Explore /
  • Poster
  • / Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study.

Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study.

Abstract Poster

Authors

Ivan Borbath

Ivan Borbath

Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium

Ivan Borbath , Jean-Luc Van Laethem , Mark Karwal , Chris Verslype , Hans Van Vlierberghe , Adel Kardosh , Francesca Bergamo , Per Stål , Debashis Sarker , Daniel H. Palmer , Julien Edeline , Stéphane Cattan , Masatoshi Kudo , Ann-Lii Cheng , Sadahisa Ogasawara , Abby B. Siegel , Ken Hatogai , Anran Wang , Arndt Vogel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT02702414

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4109)

DOI

10.1200/JCO.2022.40.16_suppl.4109

Abstract #

4109

Poster Bd #

96

Abstract Disclosures

Similar Posters

First Author: Lorenza Rimassa

First Author: Anthony B. El-Khoueiry

First Author: David F. McDermott

First Author: Jae-Lyun Lee